Comparison of clinical and neuroimaging features of neurodegenerative disease using [11C]PBB3 PET

Comparison of clinical and neuroimaging features of neurodegenerative disease using [11C]PBB3 PET - Comparison of clinical and neuroimaging features of neurodegenerative disease using [11C]PBB3 PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018774

Enrollment

220

Registered

2015-09-15

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegenerative disease

Interventions

We use [11C]PBB3 as tau radiotracer by administration intravenously.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: each disease;20 healthy control;40

Exclusion criteria

Exclusion criteria: Persons who several doctors think it is difficult participate the trial.

Design outcomes

Primary

Measure	Time frame
About each neurodegenerative disease,We compare [11C]PBB3 PET imaging with MRI and clnical syndrome.	—

Countries

Japan

Contacts

Public ContactKazunori Imai

Nagoya University Department of Neurology

imai.kazunori@b.mbox.nagoya-u.ac.jp052-744-1975

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026